Jim Mullen is a recognized biotech leader with more than 40 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. He recently served at Editas Medicine, a clinical-stage biotechnology company, where he was chair from March 2018 until February 2021, when was appointed as president and CEO. In June 2022, Mullen became executive chair of Editas until May 2023. Previously, he served as CEO of Patheon NV, a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific Inc. (Thermo Fisher) in August 2017. Before joining Patheon, Mullen was CEO and president at Biogen Inc., one of the world’s largest biotechnology companies. Prior to being named CEO, he held various operating positions at Biogen, including chief operating officer; vice president, International; and vice president, Operations. Mullen also serves on the board of directors of Thermo Fisher Scientific.